1/23
Comprehensive vocabulary flashcards covering the pathophysiology, epidemiology, diagnostic criteria, classification schemes, and clinical management strategies discussed in Class 1 of the Diabetes Fundamentals Series 2026.
Social Drivers of Health (SDOH)
The economic, environmental, political, and social conditions in which individuals live that are largely beyond direct personal control and account for significant disparities in clinical outcomes and health inequality.
Person-Centered Care
An approach to healthcare that considers an individual's comorbidities and prognoses, respects individual preferences, needs, and values, and ensures that the person's values guide all clinical decision-making.
ADCES7 Self-Care Behaviors™
A framework identifying seven essential self-care behaviors for successful diabetes management: healthy eating, being active, monitoring, taking medication, problem solving, reducing risks, and healthy coping.

Pancreatic Beta Cells
Endocrine cells comprising approximately 60% of pancreatic islets that produce and secrete insulin and amylin to lower blood glucose levels.
Pancreatic Alpha Cells
Endocrine cells comprising approximately 30% of pancreatic islets responsible for secreting glucagon, which elevates circulating blood glucose.
Pancreatic Delta Cells
Endocrine cells comprising approximately 10% of pancreatic islets that secrete somatostatin.
Incretins
Gut hormones, including GLP-1 and GIP, released by L cells of the intestinal mucosa that stimulate beta-cell insulin secretion and lower glucose in response to food intake.
Diabetes Prevention Program (DPP) Lifestyle Intervention
A structured 16-session core curriculum completed within 6months (followed by 6months of maintenance) aimed at achieving at least 7% weight loss and 150minutes of moderate-intensity physical activity per week, proven to reduce type 2 diabetes risk by 58% over 3years.
Prediabetes Diagnostic Criteria
Glycemic ranges indicating elevated diabetes risk: Fasting Plasma Glucose of 100–125mg/dL, 2-hour plasma glucose during a 75-g OGTT of 140–199mg/dL, or an A1C of 5.7–6.4%.
Diabetes Mellitus Diagnostic Criteria
Standard thresholds for diagnosing diabetes: Fasting Plasma Glucose ≥126mg/dL, 2-hour OGTT glucose ≥200mg/dL, random plasma glucose ≥200mg/dL with classic symptoms of hyperglycemia, or an A1C ≥6.5%.
Estimated Average Glucose (eAG)
A clinical calculation translating an A1C percentage into average glucose units using the formula eAG=28.7×A1C−46.7, where each 1% increase in A1C represents approximately 29mg/dL in blood glucose.
Type 1 Diabetes Mellitus
An autoimmune form of diabetes accounting for 5–10% of cases, characterized by immune-mediated pancreatic beta-cell destruction, insulin sensitivity requiring 0.5–1.0units/kg/day of exogenous insulin, and a peak onset typically between ages 10–14years.
Islet Autoantibodies
Serum antibodies directed against beta-cell components used to diagnose or predict type 1 diabetes, primarily including glutamic acid decarboxylase (GAD), islet antigen 2 (IA-2), zinc transporter 8 (ZnT8), and insulin autoantibodies.
Stage 1 Type 1 Diabetes
The presymptomatic phase of type 1 diabetes defined by the presence of two or more islet autoantibodies with normoglycemia.
Stage 2 Type 1 Diabetes
The presymptomatic phase of type 1 diabetes defined by the presence of multiple islet autoantibodies accompanied by dysglycemia (FPG 100–125mg/dL, 2-h PG 140–199mg/dL, or A1C 5.7–6.4%).
Stage 3 Type 1 Diabetes
The clinical phase of type 1 diabetes marked by overt hyperglycemia and symptoms that meet standard diagnostic criteria.
Teplizumab (Tzield)
An anti-CD3 monoclonal antibody administered as a 14-day intravenous infusion that delays the progression from stage 2 to clinical stage 3 type 1 diabetes (median delay of 48.4months vs. 24.4months for placebo) in eligible individuals aged ≥8years.

Acanthosis Nigricans
A cutaneous marker of hyperinsulinemia and insulin resistance presenting as velvety, hyperpigmented plaques in skin folds such as the neck, axillae, groin, knuckles, and elbows.
The Noxious Nine
The multi-organ pathophysiological defects driving type 2 diabetes: decreased beta-cell insulin secretion, increased alpha-cell glucagon secretion, elevated hepatic glucose production, increased lipolysis, decreased muscle glucose uptake, neurotransmitter dysfunction, increased renal glucose reabsorption, decreased incretin effect, and hypercortisolism.
Type 3c Diabetes (Pancreatogenic Diabetes)
A form of diabetes accounting for 5–10% of cases, characterized by structural and functional loss of insulin secretion secondary to exocrine pancreatic dysfunction (most frequently caused by chronic or acute pancreatitis in 70% of cases, pancreatectomy, trauma, neoplasia, or cystic fibrosis).

Gestational Diabetes Mellitus (GDM)
Glucose intolerance first identified during pregnancy, typically screened for between 24–28weeks of gestation, which confers a 50% risk of developing type 2 diabetes within 5years postpartum.
One-Step Strategy for GDM (IADPSG Consensus)
A diagnostic protocol using a fasting 75-g OGTT with plasma glucose evaluated after at least an 8-hour overnight fast; diagnosis is confirmed if fasting ≥92mg/dL, 1-hour ≥180mg/dL, or 2-hour ≥153mg/dL.
Two-Step Strategy for GDM (NIH Consensus)
A screening approach beginning with a non-fasting 50-g oral glucose load (Step 1); if the 1-hour plasma glucose is ≥130–140mg/dL, a diagnostic fasting 100-g 3-hour OGTT (Step 2) is performed, requiring at least 2 of 4 thresholds to be met or exceeded (95,180,155,140mg/dL).
Empowerment Approach
A diabetes education philosophy founded on helping individuals recognize and cultivate their internal capacity to take responsibility for their own lives and diabetes self-management decisions.